Breaking News

AbbVie, Voyager Enter Exclusive Alzheimer’s Alliance

Aims to develop and commercialize vectorized antibodies against tau for Alzheimer's and other neurodegenerative diseases

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie and Voyager Therapeutics have entered an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer’s disease and other neurodegenerative diseases. The collaboration combines AbbVie’s monoclonal antibody expertise, global clinical development and commercial capabilities with Voyager’s gene therapy platform that enables generating adeno-associated viral (AAV) vectors for the...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters